Phase 1 N=54 Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)
Bacterial Infection
Primary: Number of Participants With Treatment-Emergent Adverse Events — 0; 1; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=21 Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers
Campylobacter Jejuni Infection
Primary: Count of Participants With Adverse Events — 0; 1; 3; 1 Participants
Phase 1 N=20 Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
Cough · Healthy
Primary: Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-Infinity]) of Camlipixant — 3851.24; 1423.84 Hours*nanograms per milliliter
Phase 1 N=9 MMV533 Plasmodium Falciparum Volunteer Infection Study
Malaria
Primary: The Activity of Single Oral Doses of MMV533 (Name of Investigational Medicinal Product) on Clearance of Plasmodium — 42.17; 158.03; 187.57 PRR48=parasite reduction ratio…
Phase 1 N=6 A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
Breast Cancer
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] — 0 Participants
Phase 1 N=20 A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults
Healthy Volunteers
Primary: Maximum Observed Concentration (Cmax) of BOS — 692.9; 604.1 picograms per milliliter (pg/mL)
Phase 1 N=1 ATRi Transition Rollover Study
Advanced Stage Solid Tumors
Primary: Number of Participants With Adverse Events (AEs) and Treatment Related AEs — 1; 0 Participants
Phase 1 N=28 Bioequivalence Study of Test and Reference 120 mg Etoricoxib Film-coated Tablets in Healthy Volunteers
Bioequivalence · Healthy Subjects
Primary: Maximum Plasma Concentration (Cmax) — 1948.656; 1916.300 ng/mL
Phase 1 N=38 Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)
Cognitive Impairment Associated With Schizophrenia
Primary: Mean Inter-trial Coherence (ITC) Magnitude of 40 Hz-derived Auditory Steady-state Response (ASSR) in HC and SZ Participants at Baseline — 0.432; 0.364 ITC (40Hz*msec)
Phase 1 N=34 Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Events Signs and Symptoms: Pain and/or Tenderness — 5; 4; 1; 6 Participants
Phase 1 N=26 A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain
Radiculopathy Lumbar
Primary: The Number of Participants With Adverse Events by Dose (Part A) — 1; 1; 2; 2 participants
Phase 1 N=30 Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
Skin Cancer
Primary: DNA Damage Level by Cyclobutane Pyrimidine Dimer (CPD) Measurement — 2.48; 2.18; 2.64; 1.14 Optical Density Units — p=0.003
Phase 1 N=27 A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants
Healthy Participants
Primary: Part A: Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 0; 0; 0; 1 Participants
Phase 1 N=10 The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA
Healthy Participants
Primary: Rates of Hepatic Mitochondrial Oxidation — 262; 149 micromol/min
Phase 1 N=22 A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
Schizophrenia
Primary: Change From Baseline in Dopamine Synthesis Capacity at Week 2 Using 18F-DOPA. — -0.0007; -0.0008; -0.0006; -0.0008 Kicer — p=0.0072